- Pluristem's (PSTI +2%) PLacental eXpanded (PLX) cells produce positive results in pre-clinical trials of rats with tendon injuries.
- "PLX-treated tendons demonstrated better early structural properties at two and four weeks compared to saline-treated controls," Pluristem says.
- "As an 'off the shelf' cell source, PLX cells could provide an effective option to improve tendon healing," says Dr Scott Rodeo, the Principal Investigator for the study.
- PLX is undergoing a Phase I/II clinical trial in Germany to test it in muscle injuries. (PR)
From other sites
at 4-traders.com (Mar 24, 2015)
Pluristem Therapeutics : Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indicationsat 4-traders.com (Mar 24, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Mar 18, 2013)
at MarketWatch.com (Sep 13, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs